Discontinued — last reported Q1 '18
Xylem Allowance for Doubtful Accounts Receivable (Current) decreased by 22.1% to $53.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $53.00M to $53.00M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 8.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $41.00M | $43.00M | $44.00M | $37.00M | $41.00M | $46.00M | $50.00M | $36.00M | $45.00M | $55.00M | $56.00M | $46.00M | $54.00M | $60.00M | $59.00M | $53.00M | $61.00M | $66.00M | $68.00M | $53.00M |
| QoQ Change | — | +4.9% | +2.3% | -15.9% | +10.8% | +12.2% | +8.7% | -28.0% | +25.0% | +22.2% | +1.8% | -17.9% | +17.4% | +11.1% | -1.7% | -10.2% | +15.1% | +8.2% | +3.0% | -22.1% |
| YoY Change | — | — | — | — | +0.0% | +7.0% | +13.6% | -2.7% | +9.8% | +19.6% | +12.0% | +27.8% | +20.0% | +9.1% | +5.4% | +15.2% | +13.0% | +10.0% | +15.3% | +0.0% |